Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes: Idiopathic Hypersomnia Could Expand Lumryz Into A Larger Growth And Margin Driver
Alkermes is positioned for significant growth through LUMRYZ's potential expansion into idiopathic hypersomnia (IH), following positive Phase 3 results. LUMRYZ's IH indication could drive incremental revenue, leveraging existing commercial infrastructure and delivering operating leverage with a limited SG&A increase. ALKS faces a 10% royalty to Jazz Pharmaceuticals on non-narcolepsy LUMRYZ sales post-March 2028, but the opportunity remains financially meaningful.
Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise
Alkermes plc is upgraded from Hold to Buy, driven by robust revenue growth, pipeline momentum, and strategic positioning in sleep and CNS disorders. Acquisition of Avadel and Lumryz launch propel >20% revenue growth in 2026; adjusted EBITDA guidance is $370–410M despite a GAAP net loss. Alixorexton's strong Phase 2 data in narcolepsy and IH, plus advancing orexin pipeline, underpin multi-billion-dollar long-term revenue potential.
Why Is Alkermes (ALKS) Up 1.7% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know
Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel momentum into the rest of 2026.
Alkermes plc (ALKS) Q2 2026 Earnings Call Transcript
Alkermes plc (ALKS) Q2 2026 Earnings Call Transcript
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down
ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz adding momentum. The company maintains its 2026 revenue view.
Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alkermes Q2 Earnings Call Highlights
Alkermes NASDAQ: ALKS reported second-quarter 2026 revenue of $496 million, supported by growth across its proprietary product portfolio and the first full-quarter contribution from LUMRYZ following the company's acquisition of Avadel. The company also highlighted progress across its orexin development pipeline and reiterated most of its full-year financial outlook.
Alkermes (ALKS) Reports Break-Even Earnings for Q2
Alkermes (ALKS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.52 per share a year ago.
Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton
Alkermes plc maintains a Buy rating, driven by the accretive Avadel Pharmaceuticals acquisition and strong pipeline progress. Company bolstered its hypersomnolence portfolio with LUMRYZ, which delivered robust early sales and revenue momentum post-acquisition. Positive phase 2 data for alixorexton in narcolepsy type 2 and ongoing phase 3 Brilliance Studies underpin a compelling growth thesis.
